Inflammation and oxidative stress both play a key role in the induction and the progression of Chronic Kidney Disease (CKD). Especially in diabetic patients this is a concern. Chronic Low Grade Inflammation is most likely a major factor in the pathogenesis and progression of diabetic nephropathy.
This is a reason why a new company started working in this field with PEA.
The company Prismic is focussing to support the further clinical development with PEA and to prove the concept that palmitoylethanolamide is a useful therapy in diabetic nephropathy.
The issue with the company follows up has been debated already since years in naturpath circles, that is that by reducing low grade chronic inflammation and by inhibiting oxidative stress, molecules such as PEA may reduce risk factors associated with the progression of Chronic Kidney Disease (CKD).
Especially since PEA is devoid of side effects, and does not use liver or kidney pathways for its metabolism, PEA is a very good candicate for treating inflammation in chronic nephropathy.